First-line Therapy for metastatic hormone-sensitive Prostate Cancer (mHSPC) Randomized, double-blind Phase III Study of Pembrolizumab (MK-3475) plus Enzalutamide plus ADT compared with Placebo Plus Enzalutamide Plus ADT in Participants with metastatic hormone-sensitive Prostate Cancer (mHSPC) (KEYNOTE-991) - AP 108/19 of the AUO

被引：0
|
作者：
Rexer, H. [1 ]
Retz, M. [2 ]
Hammerer, P. [3 ]
机构：
[1] AUO Geschaftsstelle, Schwarz, Germany
[2] Tech Univ Munich, Urol Klin & Poliklin, Klinikum rdl, Munich, Germany
[3] Deutsch Krebsgesellschaft eV, Organgrp Arbeitsgemeinschaft Urol, Berlin, Germany
来源：
UROLOGE | 2021年 / 60卷 / 07期
关键词：
D O I：
10.1007/s00120-021-01570-0
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：987 / 988
页数：2
相关论文
共 50 条
  • [31] Randomized, double-blind Phase III Study of Pembrolizumab (MK-3475) plus Docetaxel plus Prednisone versus Placebo plus Docetaxel plus Prednisone in chemotherapy-naive metastatic castration-resistant Prostate Cancer (mCRPC) with Progress under a next-Generation Hormone Preparation (KeyNote-921) - AP 106/19 of the AUO
    Rexer, H.
    Gratzke, C.
    Graefen, M.
    UROLOGE, 2020, 59 (08): : 1006 - 1008
  • [32] Efficacy of Enzalutamide plus Androgen Deprivation Therapy in Metastatic Hormone-Sensitive Prostate Cancer by Pattern of Metastatic Spread: ARCHES Post Hoc Analyses
    Armstrong, Andrew J.
    Shore, Neal D.
    Szmulewitz, Russell Z.
    Petrylak, Daniel P.
    Holzbeierlein, Jeffrey
    Villers, Arnauld
    Azad, Arun
    Alcaraz, Antonio
    Alekseev, Boris
    Iguchi, Taro
    Gomez-Veiga, Francisco
    Rosbrook, Brad
    Lee, Ho-Jin
    Haas, Gabriel P.
    Stenzl, Arnulf
    JOURNAL OF UROLOGY, 2021, 205 (05): : 1361 - 1370
  • [33] Final Overall Survival Analysis From ARCHES: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Enzalutamide Plus Androgen Deprivation Therapy in Men With Metastatic Hormone-Sensitive Prostate Cancer
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (11) : 17 - 18
  • [34] CYCLONE 3: A Phase 3, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk metastatic hormone-sensitive prostate cancer (mHSPC)
    Piulats, J. M.
    Smith, M.
    Matsubara, N.
    Zhang, T.
    Agarwal, N.
    Mckay, R. R.
    Johnston, E.
    Sherwood, S.
    Schaverien, C.
    Fasnacht, N.
    Lithio, A.
    Nacerddine, K.
    Todenhoefer, T.
    EUROPEAN UROLOGY, 2023, 83 : S757 - S757
  • [35] Changes in bone mineral density, trabecular bone score and body composition in metastatic hormone-sensitive prostate cancer (mHSPC) patients randomized to receive androgen deprivation plus enzalutamide plus/minus zoledronic acid: The BonEnza study
    Volta, A. Dalla
    Valcamonico, F.
    Zivi, A.
    Procopio, G.
    Sepe, P.
    Del Conte, G.
    Di Meo, N.
    Foti, S.
    Zamboni, S.
    Messina, C.
    Lucchini, E.
    Rizzi, A.
    Ravanelli, M.
    Caramella, I.
    Zamparini, M.
    Milella, M.
    Suardi, N.
    Maroldi, R.
    Farina, D.
    Berruti, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S965 - S965
  • [36] The efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) on bone oligometastatic hormone-sensitive prostate cancer: A post hoc analysis of ARCHES.
    Armstrong, Andrew J.
    Iguchi, Taro
    Azad, Arun
    Villers, Arnauld
    Alekseev, Boris
    Petrylak, Daniel P.
    Szmulewitz, Russell Zelig
    Alcaraz, Antonio
    Shore, Neal D.
    Holzbeierlein, Jeffrey
    Gomez-Veiga, Francisco
    Rosbrook, Brad
    Zohren, Fabian
    Haas, Gabriel P.
    Gourgioti, Georgia
    El-Chaar, Nader N.
    Stenzl, Arnulf
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [37] CYCLONE 3: A phase 3, randomized, double-blind, placebo-controlled study of abemaciclib in combination with abiraterone plus prednisone in men with high-risk, metastatic, hormone-sensitive prostate cancer (mHSPC).
    Smith, Matthew Raymond
    Matsubara, Nobuaki
    Mckay, Rana R.
    Piulats, Josep M.
    Todenhofer, Tilman
    Zhang, Tian
    Fasnacht, Nicolas
    Sherwood, Sarah
    Johnston, Erica L.
    Schaverien, Clare
    Lithio, Andrew
    Nacerddine, Karim
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [38] Second-/Third-Line Therapy after Failure of Next-Generation-Hormone Therapy (NHA) and possibly Second-Line Therapy with Abiraterone for Patients with metastatic Prostate Cancer (mCRPC) Randomized, double-blind Phase-III Study of Pembrolizumab (MK-3475) and plus Enzalutamide Combination versus Placebo and Enzalutamide Combination in Patients with metastatic castration-resistant Prostate Cancer (mCRPC) (KEYNOTE-641) AP 107/19 of the AUO
    Rexer, H.
    Stenzl, A.
    Boegemann, M.
    AKTUELLE UROLOGIE, 2021, 52 (03) : 218 - 219
  • [39] SAABR: Single arm phase II study of androgen receptor pathway inhibitor (ARPI) plus atezolizumab plus GnRH analog (ADT) and stereotactic body radiotherapy (SBRT) to the prostate in men with de novo hormone-sensitive metastatic prostate cancer (mHSPC)
    Rathkopf, D.
    Dallos, M.
    Stein, M.
    Spina, C. S.
    Deutsch, I.
    Nguyen, C.
    Okada, A.
    Lloyd, M.
    Manarite, J.
    McBride, S.
    ANNALS OF ONCOLOGY, 2024, 35 : S995 - S996
  • [40] Darolutamide (DARO) in combination with androgendeprivation therapy (ADT) and docetaxel (DOC) in Chinese patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC) in the phase III ARASENS study
    Wang, S.
    Fu, C.
    Li, Y.
    Xing, J.
    Zhou, L.
    Yang, Y.
    Wang, H.
    Smith, M. R.
    Tombal, B.
    Hussain, M.
    Niu, Y.
    Cai, L.
    Liu, Q.
    Littleton, N.
    Li, R.
    Ye, D.
    ANNALS OF ONCOLOGY, 2023, 34 : S1572 - S1572
12345